Navigation Links
Quanterix Announces Publication of Novel Method Expanding Single Molecule Detection Capability

CAMBRIDGE, Mass., Feb. 23, 2011 /PRNewswire/ -- Quanterix Corporation, a single molecule diagnostics company providing technology with unprecedented sensitivity for the life science and in vitro diagnostics markets, today announced the online publication of a study that builds upon the company's Single Molecule Array (SiMoA™) technology by combining digital and analog detection in one straightforward measurement.  The article appears in the journal Analytical Chemistry, and highlights the ability to precisely measure proteins present at not only extremely low levels, but higher concentrations as well, effectively extending the dynamic range of immunoassays from the picomolar level down to sub-femtomolar levels in a single measurement.  

"Many diagnostic applications require tests to be sensitive as well as perform over a broad spectrum of concentrations to allow target analytes to be measured in the majority of clinical samples.  By combining the Quanterix digital approach for single molecule detection with ensemble measurements, we are able to measure proteins over a wider range than either method alone," said David Duffy, Ph.D., corresponding author of the article.

David Okrongly, Ph.D., President and CEO of Quanterix added, "The ability to accurately measure proteins over a larger concentration range, down to sub-femtomolar levels, further moves the company towards our stated goal of providing a universal platform that will improve the quality and clinical value of immunodiagnostics.  This expansion of our SiMoA technology allows us to deliver the most sensitive and precise results without sacrificing assay throughput or increasing cost in the clinical setting."

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness.  Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit

SOURCE Quanterix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Quanterix Announces New Technology Evaluation Agreement
2. Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board
3. Stereotaxis Announces Election of Joseph D. Keegan to Board of Directors
4. China Cord Blood Corporation Announces Results of 2010 Annual General Meeting
5. Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
6. Sensus Healthcare Announces Its Exhibitor Attendance at the 9th Annual South Beach Symposium™
7. Sensus Healthcare Announces the Formation of a Medical Advisory Board
8. Sigma-Aldrich Announces Organizational Changes
9. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
10. MiMedx Announces Launch of AmnioFix™
11. Savient Pharmaceuticals Announces Executive Appointments
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology:
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:5/24/2016)... -- Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the ... latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Display- Ampronix News ...
Breaking Biology News(10 mins):